DBVTF 财务： Dbv Technologies SA AI 分析

主页

股票

DBVTF

财务数据

DBVTF 财务

Dbv Technologies SA

$4.3

收盘价：Mar 27, 16:00:00 GMT-4

$4.3

盘后：Mar 27, 20:00:00 GMT-4

概述预测收益股息财务数据

收入

资产负债表

现金流量

年度

季度性

DBVTF 收入

以百万美元为单位的财务数据。财年为2月至次年1月。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
营收	3	4	15	4	5	11
营收同比增长 (YoY)	-77%	-73%	275%	-20%	-55%	-21%
营收成本	--	0	0	0	0	0
毛利润	--	3	15	4	5	11
销售、一般及管理费用	28	30	30	24	33	43
研发	95	88	71	61	57	81
营业费用	125	119	91	100	104	145
其他非经营性收入 (费用)	--	--	--	--	--	--
税前利润	-122	-114	-72	-95	-98	-159
所得税费用	0	0	0	0	0	0
净利润	-122	-114	-72	-96	-98	-159
净利润增长	39%	57.99%	-25%	-2%	-38%	-8%
稀释后流通股数	118.54	96.99	95.12	77.38	54.91	54.09
股份同比变动 (YoY)	23%	2%	23%	41%	2%	46%
每股收益 (摊薄)	-1.03	-1.17	-0.76	-1.24	-1.78	-2.95
每股收益增长率	12%	54%	-38%	-31%	-40%	-37%
自由现金流	-88	-105	-78	-52	-104	-163
每股自由现金流	--	--	--	--	--	--
毛利率	--	75%	100%	100%	100%	100%
营业利润率	-4,033.33%	-2,900%	-506.66%	-2,400%	-1,980%	-1,218.18%
净利率	-4,066.66%	-2,850%	-480%	-2,400%	-1,960%	-1,445.45%
自由现金流利润率	-2,933.33%	-2,625%	-520%	-1,300%	-2,080%	-1,481.81%
EBITDA	-116	-116	-76	-82	-87	-113
EBITDA 利润率	-3,866.66%	-2,900%	-506.66%	-2,050%	-1,739.99%	-1,027.27%
EBITDA 中的折旧与摊销	5	0	0	14	12	21
EBIT	-121	-116	-76	-96	-99	-134
EBIT 利润率	-4,033.33%	-2,900%	-506.66%	-2,400%	-1,980%	-1,218.18%
有效税率	0%	0%	0%	0%	0%	0%

Follow-Up Questions

Dbv Technologies SA 的关键财务报表是什么？



根据最新的财务报表（Form-10K），Dbv Technologies SA 的总资产为 $65，净损失为 $-114

DBVTF 的关键财务比率是什么？



Dbv Technologies SA 的流动比率是 1.71，净利 margin 为 -2,850，每股销售为 $0.04。

Dbv Technologies SA 的收入按细分市场或地理位置如何划分？



Dbv Technologies SA 最大收入来源是 Epicutaneous Immunotherapy Products，在最近的收益报告中收入为 3,837,510。就地区而言， France 是 Dbv Technologies SA 的主要市场，收入为 3,837,510。

Dbv Technologies SA 是否盈利？



不，根据最新的财务报表，Dbv Technologies SA 的净损失为 $-114

Dbv Technologies SA 有负债吗？



是的，Dbv Technologies SA 的负债为 38

Dbv Technologies SA 的流通股有多少？



Dbv Technologies SA 的总流通股为 102.58

关键数据

前收盘价

$4.3

开盘价

$4.3

当日区间

$4.3 - $4.3

52周范围

$0.0001 - $4.79

交易量

100

平均成交量

股息收益率

每股收益（TTM）

-1.04

市值

$1.1B

什么是 DBV TECHNOLOGIES？

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.

功能特性

资源